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The P2RX7 receptor is a unique member of a family of extracellular ATP (eATP)-gated
ion channels expressed in immune cells, where its activation triggers the inflammatory
cascade. Therefore, P2RX7 has been long investigated as a target in the treatment
of infectious and inflammatory diseases. Subsequently, P2RX7 signaling has been
documented in other physiological and pathological processes including pain, CNS and
psychiatric disorders and cancer. As a result, a range of P2RX7 antagonists have been
developed and trialed. Interestingly, the recent crystallization of mammalian and chicken
receptors revealed that most widely-used antagonists may bind a unique allosteric
site. The availability of crystal structures allows rational design of improved antagonists
and modeling of binding sites of the known or presumed inhibitors. However, several
unanswered questions limit the cogent development of P2RX7 therapies. Firstly, this
receptor functions as an ion channel, but its chronic stimulation by high eATP causes
opening of the non-selective large pore (LP), which can trigger cell death. Not only the
molecular mechanism of LP opening is still not fully understood but its function(s) are
also unclear. Furthermore, how can tumor cells take advantage of P2RX7 for growth
and spread and yet survive overexpression of potentially cytotoxic LP in the eATP-rich
environment? The recent discovery of the feedback loop, wherein the LP-evoked release
of active MMP-2 triggers the receptor cleavage, provided one explanation. Another
mechanism might be that of cancer cells expressing a structurally altered P2RX7
receptor, devoid of the LP function. Exploiting such mechanisms should lead to the
development of new, less toxic anticancer treatments. Notably, targeted inhibition of
P2RX7 is crucial as its global blockade reduces the immune and inflammatory responses,
which have important anti-tumor effects in some types of malignancies. Therefore,
another novel approach is the synthesis of tissue/cell specific P2RX7 antagonists.
Progress has been aided by the development of p2rx7 knockout mice and new
conditional knock-in and knock-out models are being created. In this review, we seek
to summarize the recent advances in our understanding of molecular mechanisms
of receptor activation and inhibition, which cause its re-emergence as an important
therapeutic target. We also highlight the key difficulties affecting this development.
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INTRODUCTION
P2RX7 is a 595aa protein belonging to the ionotropic purinergic
P2X subfamily which consists of seven members, P2X1-7
(Burnstock and Knight, 2004). P2Xs represent an ancient
form of purine chemical messenger reception, with relatives
now cloned from species as diverse as Homo sapiens and
Dictyostelium (Burnstock and Verkhratsky, 2012). All family
members are trimeric ligand-gated ion channels displaying a
preference for cations. Their subunits comprise intracellular
N and C termini, two transmembrane domains and a large
intervening extracellular region containing the ATP binding
site (Surprenant et al., 1996). P2RX7, originally characterized
by Cockcroft and Gomperts as the ATP4− receptor in rat
mast cells (Cockcroft and Gomperts, 1980) was previously
also known by the name of P2Z receptor, responsible for the
eATP-dependent lysis of macrophages (Surprenant et al., 1996).
This confusion arose in part due to its many characteristics,
which make this receptor entirely distinct from other P2Xs.
These include uniquely lower affinity for eATP: EC50 >1mM
at physiological ion concentrations (Yan et al., 2010) and the
ability to induce membrane blebbing and cell death. As such,
P2RX7 is perhaps best known for its role in regulating innate
and adaptive immune responses and is expressed on virtually
all cell types of the immune system (Burnstock and Knight,
2017). Macrophages and microglia express high levels of P2RX7
(He et al., 2017; Young et al., 2017) and are perhaps the best
studied cells in relation to receptor function both in vitro and
in/ex vivo (Csóka et al., 2015). However, P2RX7 has a huge
functional repertoire being involved in phenomena as diverse as
inflammation (Rissiek et al., 2015), proliferation (Monif et al.,
2010), migration and invasion (Qiu et al., 2014), metabolism
(Amoroso et al., 2012), autophagy (Young et al., 2015), cell
death (Massicot et al., 2013), and neurotransmission (Sperlágh
et al., 2002). P2RX7 over-expression and over-activation have
been implicated in numerous physiological/pathophysiological
processes where, intriguingly, P2RX7 activation can result in
both positive and negative outcomes depending on a host of
factors such as intensity and duration of the agonist stimulus
(Hanley et al., 2012), severity of pathogen virulence/infection
(Figliuolo et al., 2017), the cell type (Cortés-Garcia et al., 2016;
Young et al., 2017), extracellular ion concentration (Virginio
et al., 1997), phospholipid membrane composition (Karasawa
et al., 2017), co-factor activity (Migita et al., 2016), enzymatic
processing (Young et al., 2017), polymorphic variations (Fuller
et al., 2009; Ursu et al., 2014), and non-ATP agonist activation
(Hong et al., 2009). The latter occurs during innate immune
responses through the release of damage-associated molecular
patterns (DAMPs; e.g., DNA, RNA, HMGB1, etc.) or pathogen-
associated molecular patterns (PAMPs, e.g., LPS) either directly
or via Toll-like receptors (TLRs). Specifically, TLR2 and TLR4
have been found to directly interact with P2RX7 via biglycan
Abbreviations: eATP, extracellular Adenosine Triphosphate; BMDNs, Bone
Marrow Derived Neutrophils; DAMPs, Danger Associated Molecular Patterns;
PAMPs, Pathogen Associated Molecular Patterns; TLR, Toll-like receptor; NLRP3,
NOD-like receptor protein 3; MMP, Matrix metalloproteinase; IL, Interleukin.
(Babelova et al., 2009). Classically, once eATP activates P2RX7,
TLR4-mediated pro-IL-1β processing is followed by potassium
eﬄux, NLRP3/ASC inflammasome assembly and caspase-1-
dependent IL-1β maturation and release (Perregaux and Gabel,
1994; Pelegrin et al., 2008; Dubyak, 2012). Other P2RX7-
dependent inflammatory activators include IL-6, ROS (Munoz
et al., 2017), other caspases and MMPs (Gu and Wiley, 2006;
Young et al., 2017). P2RX7 role in the adaptive immune response
is to directly activate T cell populations, being a pre-requisite
for IL-2 release, to orchestrate the balance between Treg and
T helper cell populations, with receptor activation favoring the
formation of T helpers and its blockade having the opposite
effect (Schenk et al., 2011; Cekic and Linden, 2016). However,
while its role in macrophages, microglia, and T cells has been
researched extensively, our understanding of the role of P2RX7
in other immune cell types is still evolving. Neutrophils, for
example, first thought devoid of P2RX7 expression in humans
(Martel-Gallegos et al., 2010), have risen to the fore with the
recent demonstration of neutrophil-mediated orchestration of
the IL-1β/NLRP3 response in BMDNs (Karmakar et al., 2016).
Exploration of tumor-associated immune cell populations has
also led to the discovery that macrophages and microglia are
not the only cells to express high levels of P2RX7. Tumors
also display upregulated P2RX7 expression, reaching levels far
exceeding that of macrophages (Young et al., 2017). In fact, all
tumor types listed in The Cancer Genome Atlas were found
to have upregulated levels of P2RX7 expression, with sub-type-
specific mutation patterns highlighting the significant potential
for novel therapeutic approaches in this area (Young et al., 2017).
Compared to other P2X receptors, P2RX7 possesses an
extra-long intracellular C-terminus with additional 200 amino
acids. Mutations at various locations in this region have been
associated with loss of diverse physiological functions such as LPS
binding (Denlinger et al., 2001), post-translational modifications
(Gonnord et al., 2009), membrane targeting (Smart et al.,
2003) and large pore formation (Feng et al., 2006). P2RX7
stimulation at lower-end eATP doses opens a cation-selective
plasma membrane channel permeable to Ca2+, Na+, and K+.
Chronic/sustained eATP dosing reveals the second facet to
P2RX7 signaling; the formation of a non-selective large pore
(LP), permeable to molecules of up to 900 Da, such as dyes
(EtBr, 314 Da; YO-PRO-1, 376 Da and Lucifer Yellow, 457 Da
Adinolfi et al., 2005). Thus, P2RX7 can display the properties
of a prototypic cytotoxic receptor. The inherent insensitivity
to eATP coupled with dire consequences of receptor over-
stimulation prompted the belief that this low agonist affinity
might be a safe-guard against potentially damaging receptor-
mediated inflammatory cascade activation through the release
of IL-1β, additional eATP or other DAMPs. Indeed, although
healthy interstitial eATP levels are maintained at nanomolar
levels or below, it has been shown that the eATP concentration
around sites of inflammation can increase several fold (Morciano
et al., 2017). For example, eATP around damaged cells or
dystrophic muscle fibers can reach 5–10mM (Di Virgilio, 2000;
Hetherington et al., 2001) and in the tumor microenvironment,
levels of >700µM have been recorded (Pellegatti et al.,
2008). The tonic, low-level vs. chronic high-level receptor
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stimulation have very different outcomes, indeed. Moreover,
the balance and fine tuning of the molecular controls that
govern these responses may underlie some of the most exciting
new possibilities for therapeutic manipulation. Efforts in this
area have been hampered by the lack of a P2RX7 crystal
structure. However, recent successful crystallizations and 3-D
reconstructions include both the 356 aa (without the C-terminal
tail) Panda (Ailuropoda melanoleuca) pdP2RX7 (Karasawa and
Kawate, 2016) as well as the truncated variant (lacking 27 N-
and 214 C-terminal aa residues) of the chicken ckP2RX7 (Kasuya
et al., 2017). These developments permit rational mechanistic
studies (Karasawa and Kawate, 2016) with exciting novel insights
into the specific mechanisms of both permeability and drug
interactions. Appreciating the number of recent reviews on
P2RX7 as a therapeutic target (Burnstock and Knight, 2017; Di
Virgilio et al., 2018a; Savio et al., 2018) in this paper we discuss
recent developments in P2RX7 drug design and repurposing,
highlighting the potential new therapeutic applications of these
drugs in human disorders.
RECENT DEVELOPMENTS IN P2RX7
CRYSTALLOGRAPHY
Crystal structures for zebrafish P2RX4 (Kawate et al., 2009),
then human P2RX3 (Mansoor et al., 2016) gave the first
insights into conserved mechanisms of action: the ATP binding
pocket, subunit interactions and conformation changes upon
agonist binding (i.e., predictions of gating and opening) (Hattori
and Gouaux, 2012). Individual subunits of these crystallized
receptors (zebrafish and human alike) adopt “dolphin-shaped”
conformations (see Kawate et al., 2009; Karasawa and Kawate,
2016). The aforementioned recent crystallizations of both
ckP2RX7 (Kasuya et al., 2017) and pdP2RX7 (Karasawa and
Kawate, 2016) confirmed this structure. 3-D reconstructions of
trimeric subunit interactions also confirm three equivalent ATP
binding site locations at subunit interfaces. More excitingly, the
pdP2RX7 structure has revealed a completely novel allosteric
site situated in the groove formed between two adjacent
subunits, which is completely distinct from the ATP binding
site (Karasawa and Kawate, 2016). ckP2RX7 and pdP2RX7
share ∼62 and 85% homology with human P2RX7A (Karasawa
and Kawate, 2016), respectively. Unfortunately, both crystal
structures lack the C-terminal, intracellular tail region, so
important for the receptor function (see below). Achieving
the complete P2RX7 3-D structural resolution remains an
unclaimed trophy. However, even the partial pdP2RX7 structure
has revealed some unexpected features. When expressed in
liposomes, the pdP2RX7 triggered LP formation despite lacking
the C-terminus. The proposed mechanism was the regulatory
dependence of the P2RX7 large pore on the membrane lipid
composition, where the cholesterol level played a significant role:
increases in membrane cholesterol correlated with reductions
in membrane fluidity and LP formation in this liposome-based
system (Karasawa et al., 2017). The singularly unique aspect
of the pdP2RX7 3-D modeling however, was the discovery of
a new allosteric binding site, distinct from the ATP-binding
pocket, at each subunit interface. The structurally unrelated
antagonists A740003, A804598, AZ10606120, GW791343, and
JNJ47965567 all were shown to bind this allosteric “groove”
between subunit faces (Karasawa and Kawate, 2016). Kawate
et al., used functional fluorescence anisotropy-based assays
to show that these compounds effectively act as “door-stops”
or “wedges,” preventing the narrowing of this groove during
the turret-like conformational rotation during channel dilation
upon agonist binding. Mutational replacement of residues with
“bulkier” cysteines resulted in effective narrowing of the inter-
subunit groove and reduced channel opening kinetics. Thus, we
now know that it is the spatial filling of this new inter-subunit
non-competitive hydrophobic pocket, which is the determining
factor in antagonist selectivity and potency. The pocket itself
is composed of β-strand residues (β4, β13, and β14) with
hydrophobic interactions at positions deep inside the pocket
(F95, F103, M105, F293, and V312) (Karasawa and Kawate,
2016). See Figure 1 for structural representations of the eATP
binding pocket and the allosteric antagonist binding groove.
The remaining limitation is the structural resolution
(∼3.2∼3.6 Å), which does not currently facilitate definitive
predictions of bond angles or side chain-drug interactions.
However, the main dimensions of the pocket are clearly
defined and this finding have opened the door for significant
strategic antagonist developments through targeted screening
and rational design approaches. Moreover, with the apparent
absence of this allosteric site in the known P2RX3 and P2RX4
crystal structures, there is a potential for the development of
highly P2RX7-selective drugs. However, since ATP binding
was also found to narrow the groove (Karasawa and Kawate,
2016), further functional studies are required to determine the
accessibility of this allosteric site under conditions of high eATP
concentration. Hence, the groove might theoretically be less
accessible due to continued receptor activation, which could have
implications for therapeutic applications. Moreover, positive
allosteric agonists such as polymyxin B (Ferrari et al., 2004)
may share this novel allosteric site or indeed may occupy other
distinct sites. Such intricacies remain unresolved but the crystal
structure makes further studies possible.
P2RX7 KINETICS: CHANNEL BECOMES
PORE?
It was the 3-D structure predictions of P2RX4, which first
suggested ion flux upon agonist binding to be initiated through
the rotation of six helical transmembrane domains of the trimeric
receptor (Hattori and Gouaux, 2012). Once TM2 Val335-Leu346
moves, the channel gate is opened and current may flow as
directed by the membrane potential (Li et al., 2008). However,
P2RX7 ion flux studies at the upper-end eATP concentrations
(typical for damaged tissues) are hampered by what appears
to be the biphasic nature of the channel, leading to a second
mode of opening. Given that pathological P2RX7 responses have
been linked to the activation of this large pore, this has been a
singularly enigmatic and controversial issue in the P2RX7 field.
Chronic receptor activation under the appropriate conditions
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FIGURE 1 | Recent P2RX7 structural developments: the ATP binding pocket and the allosteric groove. (A) PyMOL (pymol.org) generated surface plot of P2RX7 trimer
using RCSB PDB data file (rcsb.org) for chicken variant bound to the competitive antagonist TNP-ATP (structure 5XW6, 3.1A). ROI shows the ATP binding pocket
(RHS, upper), PyMOL Video file gives structural overview of the trimer with detailed orientations of the ATP binding pocket and the central ion channel (see
Supplementary Material Video S1). RCSB PDB generated images show location of the ATP binding pocket in relation to the newly discovered allosteric site on the
monomer (B) and at the subunit interface of the trimer, forming an allosteric groove—here shown occupied by A740003 antagonist (C). When imaged together from
intracellular projection, the three allosteric grooves appear as a Shuriken, whose rotation is impeded by the allosteric antagonist A740003 (D). (E) Cartoon
representation of the relationship between the agonist binding site and the allosteric antagonist-binding groove. Adapted from Karasawa and Kawate (2016), with
permission.
unquestionably facilitates massive membrane depolarization,
dye permeability and, in some circumstances, cell death via
mechanisms that might be cell-specific and even unique (e.g.,
pyroptosis, autosis etc.). However, the pore opening is reversible.
Moreover, mechanism(s) behind these effects remained elusive.
Two very mechanistically distinct hypotheses tried to explain the
large pore phenomenon. One that P2RX7, under conditions of
chronic eATP stimulation, recruits a secondary pore complex.
The fact that P2RX7 expression alone in Xenopus oocytes
proved insufficient to induce pore formation in these cells
seemingly supported the role of either some accessory protein
or other as yet unknown accessory mechanism (Petrou et al.,
Frontiers in Chemistry | www.frontiersin.org 4 June 2018 | Volume 6 | Article 248
Young and Górecki P2RX7 as a Therapeutic Target
1997), with pannexin1 (Panx1) channels being pointed out
as the main candidate (Pelegrin and Surprenant, 2006). The
second hypothesis is that the P2RX7 trimer can further change
conformation resulting in ion channel to pore dilation (Browne
et al., 2013). The LP-through-Panx1 theory is complex in its
regulatory constitution, with multiple splice variants and cell-
specific expression patterns to contend with (Ma et al., 2009).
Moreover, there is evidence that the P2RX7 LP formation is
retained in Panx1−/− cells (Qu et al., 2011; Hanley et al., 2012;
Alberto et al., 2013) and that the P2RX7 trimer can form this
LP structure alone (Browne et al., 2013; Karasawa et al., 2017).
However, the existence of P2RX7 in two opening states was not
supported by recent single-channel electrophysiological studies,
which provided no evidence for dilation of the hP2X7R channel
on sustained eATP stimulation (Pippel et al., 2017). Indeed,
it was the discrepancy between the receptor activation data
obtained by whole-cell vs. single-channel currents and via dye
permeability, which triggered the notion that the LPmust involve
an additional molecular entity. Interestingly, a recent review
seems to reconcile some of the seemingly contradictory findings
(for a comprehensive discussion see Di Virgilio et al., 2018b). The
authors argue that the model of channel-to-pore transition might
have resulted from the different kinetics of fluorescence increases
evoked by Ca2+ sensors in response to calcium influx (rapid)
and the florescence fromDNA dye binding (slow). Consequently,
the LP formation may occur concomitantly with the opening
of the ion channel and the two signals increasing over distinct
time-scales. This model fits with recent data that the P2RX7 pore
can dilate sufficiently to allow Yo-Pro permeation (Karasawa
et al., 2017). However, as specific mutations (the nfP2RX7)
or splicing affecting the C-terminus of P2RX7 abolish LP dye
uptake but not ion channel functions, we may not have the
full explanation yet. The picture should become clearer as we
move closer to a complete 3-D crystal structure determination
and understand the receptor interactome better. For instance,
demonstration of cholesterol/membrane lipid-specific controls
over pore dilation (Karasawa et al., 2017) could explain the
inherent difficulties associated with successful patch-clamping
involving the LP. The physical act of clamping a locality of the
cell membrane may simply introduce sufficient rigidity to inhibit
phospholipid movement in the vicinity of P2RX7. No doubt,
this debate will continue, resulting in some ingenious technical
development before the final conclusion is reached.
An additional level of complexity exists around the selectivity
of the P2RX7 LP, which displays a preference for cations
or anions under different physiological conditions and in
different cell types as well as in individual cells within a
clonal population: In P2RX7 transfected HEK293 cells, Lucifer
Yellow (LY) uptake displays intracellular Ca2+ dependence at
rat P2RX7, but not mouse P2RX7 expressed in Raw264.7 cells.
In the same study, EtBr uptake showed no such dependence
(Cankurtaran-Sayar et al., 2009). In macrophages, no such
calcium dependence occurs, but distinct pathways do exist, as
evidenced by preferential uptake of cationic or anionic dyes by
individual cells <100 microns apart in the same dish (Schachter
et al., 2008; Cankurtaran-Sayar et al., 2009). Our own studies
have confirmed this uptake selectivity in dystrophic myoblast
populations (Figure 2). Analysis of the fluorescent signal kinetics
of LY vs. DNA binding dyes might be useful as the latter binds
irreversibly and the difference in the dye uptake might be a
reflection of cell health rather than the P2RX7 permeability
function. Undoubtedly, understanding this mechanism might
lead to tailored therapeutic approaches, with a particular scope
in tumor cells.
Furthermore, irrespective of the mechanistic unknowns
and controversies, the real ambiguity had always been the
physiological relevance and function of this P2RX7 LP. The first
demonstration of a functional link has been identification of
a reciprocity between P2RX7 LP opening and autophagosome
formation, where the one is indispensable for the other (Young
et al., 2015). Given the recent progress in our understanding of
the importance of autophagy-dependent processes in physiology
and a range of human pathologies as diverse as neurological
/neurodegenerative diseases (Alzheimer’s, dementia, Parkinson’s,
and MLS), muscular dystrophies, infectious, lysosomal storage
diseases, Crohn’s, cancers and aging (Young et al., 2009, 2015;
Rubinsztein et al., 2011; Nikoletopoulou et al., 2015; Qian
et al., 2017), this link may suggest a potential for tuning
autophagic responses in diverse human pathologies using P2RX7
modulation.
The relationship between pore formation and cell death
is complex and also remains unclear; is pore formation
a pre-requisite for P2RX7-dependent cell death? Given the
controversies over the question whether the influx of ions
through the channel is observed prior to the pore formation, we
do not have a full answer. Working with these two facets involves
independent conditions and very different experimental setups.
The channel is mostly measured by electrophys and the LP by
dye uptake. The sensitivity difference inherent to these methods
is significant and generally, channel activity is recorded within
seconds, whilst LP opening follows up to an hour later. Since
no pharmacological antagonists truly specific to the LP has been
identified, it is currently impossible to block the pore formation
without blocking the channel. Hence, P2RX7-dependent death
might be attributed to the channel without verifying pore
functions (Kong et al., 2005). Whilst P2RX7-dependent, pore-
independent cell death has been suggested in embryonic neural
progenitor cells (Delarasse et al., 2009), this experiment was
carried out using unusually high (2.5mM) BzATP concentration.
In contrast, P2RX7 activation with 100µM BzATP was shown
to induce differentiation in embryonic neural progenitor cells
in N2-containing media, where pore formation and cell death
were again not observed (Tsao et al., 2013). Yet, 300µM has
been shown to induce pore formation and cell death in adult
neural progenitors in artificial cerebral spinal fluid (Messemer
et al., 2013). This example illustrates difficulties in drawing
conclusions around LP formation being a prerequisite for cell
death as slightly different parameters will have a significant effect
on experimental outcomes. Our own data suggest that serum
content has a significant impact on the pore function (Young
et al., 2017). This factor does not affect channel functions and
is not always described in assay methodologies. The difference
in P2RX7 receptor density on various cells and in the sensitivity
of respective detection methods may also skew the analyses of
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FIGURE 2 | Selective regulation of cationic and anionic dye permeation through the P2RX7 LP. Example of differences in P2RX7 LP permeation preferences to EtBr
(cationic) and Lucifer Yellow (anionic) dyes in individual cells of a clonal population (Young and Gorecki, 2016): Compared to WT myoblasts (Left), the dystrophic mdx
myoblasts (Center) display upregulated P2RX7 expression and increased LP permeability in response to eATP (Young et al., 2015, 2017). The mdx/P2RX7−/−
myoblasts (Right) show no dye uptake under these conditions, as expected. Note that the majority of the seemingly identical cells in this clonal population shows a
clear preferential uptake of EtBr over LY upon the LP opening, which is considered to be a non-selective pore. The molecular mechanisms underlying this
phenomenon are currently under investigation as this experiment illustrates the potential for diverse LP responses in heterogeneous and functionally plastic
populations of e.g., immune cells in vivo.
channel and pore responses.Moreover, it is commonplace for one
P2RX7 activation mode to be studied without the other. Hence,
it is often difficult to make cross-study comparisons.
P2RX7 LOCALISATION, SIGNALING,
INTERACTOME, AND REGULATION
P2RX7 is a membrane-spanning receptor. Targeted mutagenesis
has implicated the C-terminal tail region in this receptor
trafficking to the membrane (reviewed in Robinson and Murrell-
Lagnado, 2013). Interestingly, nuclear P2RX7 localisation has
also been reported (Atkinson et al., 2002), with suggested roles
in modulating neuronal plasticity, albeit no follow-up studies
supported this finding. The association of P2RX7 with lipid
rafts has been demonstrated in various systems (Garcia-Marcos
et al., 2006) and may be associated with palmitoylation of C-
terminal cysteine residues (Gonnord et al., 2009), which is
a reversible modification associated with membrane targeting.
This is intriguing given the more recent demonstration of
cholesterol-mediated inhibition of both P2RX7 LP (Karasawa
et al., 2017) and channel (Murrell-Lagnado, 2017), cholesterol
being a significant constituent of lipid rafts. The idea that
P2RX7 is both targeted to and could be inhibited by lipid
raft cholesterol, suggests an as yet un-characterized mechanism
of spatial regulation through lipid raft targeting. Interestingly,
multiple tumor types show upregulation of lipid rafts and
cholesterol-depleting agents were shown to induce apoptosis in
such cells (Li et al., 2006). The existence of a P2RX7-evoked cell
death cascade silencing through cholesterol regulation in cancer
is an interesting possibility.
In this context of cancer cell targeting, the ‘non-functional’
P2RX7 (nfP2RX7) (Slater et al., 2004) is the subject of numerous
patents for epitope-specific antibody-based therapy for several
cancer types (Gilbert et al., 2017). The nfP2RX7, in fact, retains
the calcium channel functions, which are used by cancer cells to
support its growth but lacks the ability to form the large pore
and therefore not able to trigger cell death in the high eATP
environment. This conformational change might be a specific
mechanism controlling the potentially deleterious LP opening
and allowing cancer cells expressing high P2RX7 levels to survive
in the high eATP environment.
Furthermore, a feedback loop has been discovered, where
sustained activation of P2RX7 with LP opening causes release
of active MMP-2, which halts responses via the MMP-
2-dependent receptor cleavage (Young et al., 2017). This
mechanism operates in diverse cells, including macrophages,
dystrophic myoblasts, P2RX7-transfected HEK293 and also in
cancer cells. This tuning mechanism allows malignant cells to
profit from P2RX7 channel activation eliciting proliferation,
growth, migration, invasion and metabolic advantages, whilst
avoiding cell death cascades associated with the LP. Moreover,
MMP-2 is found in serum, where it displays complex regulation
via TIMP expression/activity. Therefore, P2RX7 in organs with
discontinuous capillaries, or in pathologies affecting capillary
permeability (e.g., inflammation or tumor neo-vascularisation)
may be under the regulatory control of MMP-2 cleavage balanced
by TIMPs. CD44 has been reported to allosterically positively
modulate P2RX7 activity by facilitating eATP binding through
GAG chain interactions (Moura et al., 2015). CD44 itself was
found to be a proteolytic target of MMP-2 (Young et al., 2017),
suggesting that an additional levels of regulatory control may also
exist. Given that MMP-2 inhibition can re-open the P2RX7 LP
in cancer cells and effectively switch on the LP-associated cell
death pathway, it might be possible to develop a new generation
of cancer therapeutics promoting this P2RX7 LP formation
(Young et al., 2017). Furthermore, as P2RX7 ablation eliminated
gelatinase activity in vivo, P2RX7 antagonists could be a good
alternative to highly toxic MMP inhibitors in treatments of
inflammation and cancers.
Interestingly, non-eATP P2RX7 agonists also exist. NAD+
is perhaps the best studied here: ADP-ribosyltransferase (ART)
enzymes catalyze the transfer of ADP-ribose groups from NAD+
to arginine residue 125 of the ecto-domain lying proximal to
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the P2RX7 ATP binding site (Seman et al., 2003). Ribosylations
are covalent modifications and therefore constitutively activate
P2RX7. However, this mode of P2RX7 activation appears to
be species-specific, acting on mouse P2RX7 receptor variants,
but not human. One rationale is that the Art2b gene encoding
ART2.2 ADP-ribosyl transferase is differentially expressed
between human and mouse; mice have two active copies of
this gene, whereas in humans the transcript is translationally
silenced by three premature stop codons (Haag et al., 1994).
Moreover, this mechanism of activation is known to function
in mouse T lymphocytes but not macrophages, the latter only
display augmentation of eATP-induced receptor activation in
the presence of NAD+ (Hong et al., 2009). Therefore, this
effect may also be cell or isoform specific. Mouse but not
human has two N-terminal isoforms and the unique P2RX7k
variant is prominent in mouse T lymphocytes and particularly
sensitive to ADP-ribosylation (Rissiek et al., 2015). Therefore,
it might be the mouse-specific P2RX7k isoform responding to
NAD+ stimulus. Indeed, in the Glaxo knockout, which retains
the P2RX7k variant, receptor responses in T lymphocytes are
retained (see P2X7 knockout section below). Finally, ADP-
ribosyltransferase enzymes also display tissue specific expression
patterns, which would also contribute to the regulation of NAD+
P2RX7 signaling.
While other non-nucleotide agonists of P2RX7 have been
reported, the mode of their receptor interaction has not been
determined and may either represent competitive or allosteric
agonist/modulation. The recent structural analyses seem to
favor the latter, given the steric constraints of the ATP-binding
pocket. The immunopeptides amyloid β (Sanz et al., 2009)
and serum amyloid A (Elssner et al., 2004), along with LL-37
(Elssner et al., 2004), and polymyxin B (Ferrari et al., 2004)
have all been implicated in activating/potentiating the P2RX7
channel function through direct interactions with the receptor
extracellular loop region. Cytoplasmic agonists have also been
postulated, although these are indirect in nature: LPS binding
P2RX7 C-terminal tail was shown to lower the stimulus intensity
required for channel gating through eATP release (Yang et al.,
2015). Cytoplasmic levels of Alu-RNAwere suggested to function
in the same manner, yet without inducing eATP release (Fowler
et al., 2014).
Numerous cell-specific downstream signaling pathways are
linked with P2RX7 activation. Those associated with the
release of inflammatory mediators: caspase-1, IL-1β, IL-6, and
NLRP3/ASC activation/recruitment have already been described.
P2RX7 is also a key modulator of various signaling cascades
involved in many physiological processes, including PKC-MEK-
ERK-FOS-JUN (Tsao et al., 2013), PI3K-AKT-mTOR (Bian et al.,
2013), MyD88-NFKB (Liu et al., 2011), MMP-2/9-Dystroglycan-
CD44 (Young et al., 2017), and Calcineurin-NFATc1 (Shiratori
et al., 2010). These numerous cascades illustrate the diversity
and complexity of P2RX7 signaling, with implications for
cellular processes such as growth, proliferation, differentiation,
metabolism, migration, invasion, autophagy and also cell death.
Mechanisms of P2RX7-dependent cell death have been well
documented and are numerous, including apoptosis (Zanovello
et al., 1990) as well as several unique processes: aponecrosis
(MacKenzie et al., 2001), necroptosis (Cullen et al., 2015),
pyroptosis (de Gassart and Martinon, 2015), pseudo-apoptosis
(Roger and Pelegrin, 2011), and autosis (Draganov et al., 2015).
Autophagic cell death has also been identified (Young et al.,
2015).
The P2RX7 interactome is just as diverse. This receptor
has been suggested to directly interact with over 50 different
binding partners, most of which have been identified by
combinations of mass spectrometry, immunoprecipitation
and immunoblotting. P2RX7 interactors include soluble,
membrane-bound, peripheral, cytoskeletal and chaperone
proteins (summarized in P2X7.co.uk). This diversity of
proteins may reflect further spatial and temporal complexity.
Soluble biglycan for example, a ubiquitous extracellular matrix
(ECM) proteoglycan is responsible for coordinating the
interaction of P2RX7, TLR4, and P2RX4, facilitating NLRP3
inflammasome formation and IL-1β release (Babelova et al.,
2009). When proteolytically activated in the ECM, biglycan
itself becomes a danger signal, with the capacity to orchestrate
both sterile and infectious inflammation (Nastase et al.,
2012). Interestingly, biglycan has been studied extensively in
muscle disorders, where P2RX7 upregulation and role in both
inflammatory and non-inflammatory processes has also been
established (Young et al., 2012, 2013, 2015; Sinadinos et al.,
2015). Thus, tissue- and cell-specific modalities, as well as
expression, localization and activation of binding partners plus
influence of inflammatory mediators, all play a role in P2RX7
signaling.
P2RX7 AGONISTS AND ANTAGONISTS:
WHERE ARE WE?
As already explained, eATP is able to induce different gating
characteristics depending on concentrations around the active
site. Essentially, eATP >100µM is sufficient to activate the
channel and>100–300µMand above are necessary to induce LP
formation (Donnelly-Roberts et al., 2009). Endogenous eATP is
subject to degradation by ubiquitous extracellular nucleotidases
such as CD73 and CD39, as well as tissue-specific enzymes,
such as α-sarcoglycan (adhalin) found in skeletal muscles (Betto
et al., 1999). In this way, eATP concentrations in the extracellular
space are tightly regulated, where high concentrations are quickly
degraded to ADP, AMP and adenosine, which activate other P2X,
P2Y, and P1 receptors, respectively. Importantly, activation of
these different P1 and P2 receptors can have opposite effects to
eATP stimulation, thus creating yet another level of homeostasis
but is also confounding pharmacological studies. Moreover,
conditions where surface nucleotidases become deregulated, such
as in the case of loss of adhalin from the muscle sarcolemma
in Duchenne and limb-girdle muscular dystrophies, result in
elevated levels of eATP on the cell surface (Betto et al., 1999).
In such conditions, changes in the receptor activity might be
unrelated to its properties or expression levels. Therefore, P2RX7
specific and non-hydrolysable agonists would be useful tools
for dissecting distinct P2RX7-specific downstream responses.
While the competitive agonist benzoylated-ATP (BzATP) and
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non-hydrolysable sulfonated-ATP (ATPγS) display increased
specificity and affinity over endogenous eATP, no true P2RX7-
specific agonist has been identified so far. Hence, BzATP, with 10-
30 times higher affinity for channel gating at the human P2RX7
receptor is the most widely used (Bianchi et al., 1999) despite
its known activity at P2RX1 and P2RX3 and being metabolized
to lower MW constituents (De Marchi et al., 2016). Species-
specific differences in agonist specificity and sensitivity add an
additional level of complexity to pharmacological studies (Hibell
et al., 2000).
P2RX7 blockers are currently divided into two main
mechanistic groups: one which binds orthosterically and
competitively to the eATP binding pocket and another that
binds allosterically to sites other than the eATP site and reduces
ligand binding affinity. First generation P2RX7 antagonists
were developed in the 1990s and can now be grouped
according to their lack of specificity. Examples include Reactive
Blue 2, Suramin (and its derivatives), Coomassie Brilliant
Blue G (BBG), pyridoxal phosphate-6-azophenyl-2-4-disulfonic
acid (PPADS), 1-N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-
tyrosyl-4-phenylpiperazine (KN-62), and oxidized ATP (oATP),
see Bartlett et al. for a review (Bartlett et al., 2014). Despite
its “non-druggable” nature and lack of absolute specificity
for P2RX7 and capacity for near-infra red fluorescence upon
protein binding, BBG remains one of the most widely used
and useful reagents as it is effective at human, mouse, rat,
dog and guinea pig P2RX7. BBG also had triggered the initial
interest in therapeutic applications by showing effectiveness
in preventing eATP-induced cell death in murine models of
spinal cord injury in vivo (Wang et al., 2004; Peng et al.,
2009) and because of its blood-brain barrier (BBB) permeability.
Indeed, despite its limitations, BBG has been used widely to
block P2RX7 in various pathologies such as neuroexcitotoxicity
(Carmo et al., 2014), graft-vs.-host disease (Geraghty et al., 2017)
and muscular dystrophy (Young et al., 2012). However, as BBG
is not a specific P2RX7 antagonist, also inhibiting P2RX4 and
P2RX1 receptors, the pharmacological findings obtained with
this antagonist have been confirmed using p2rx7 KO models.
Two of these are available and have been used in the bulk of
studies: The GSK knockout carries a lacZ/Neo cassette insertion
in exon 1 (Sikora et al., 1999; Chessell et al., 2005) and Pfizer’s
(available via JAX) has a Neo cassette insertion in exon 13
(Solle et al., 2001). Importantly, in both models, P2rx7 gene
escaped complete inactivation, retaining expression of some
isoforms P2RX7k in Glaxo (Nicke et al., 2009) and P2RX7a
and P2RX7b in Pfizer (Masin et al., 2012). Specifically, T cells
and lymphocytes from the Glaxo KO have been shown to
retain P2RX7 responses, including LP function (Taylor et al.,
2009). As discussed above, this is due to the existence, in
the mouse, of the P2RX7k variant, which is driven by an
alternative promoter and its exon 1 escaping inactivation in
the GSK model. This isoform, although expressed at low levels,
displays faster activation kinetics and a lower threshold for
channel gating in comparison to the wild-type P2RX7a variant
(Nicke et al., 2009). The Pfizer KO mouse retains expression of
the alternative C-terminal variants, however these have limited
homomeric functionality and low expression levels in most
if not all cell types. Hence, while the Pfizer model can be
regarded as a functional knockout, studies using the GSK animal
should be carefully re-considered and interpreted appropriately.
Recently, new mouse models have been developed, including
some allowing the conditional, cell-type specific p2rx7 knockout.
These mice should be an invaluable resource for deciphering
the cell, tissue-specific and temporal effects of P2RX7 receptor
activation and inhibition.
Other groups of functionally related molecules have also been
shown to block P2RX7: Naturally-occurring plant compounds
such as alkaloids (Shemon et al., 2004), synthetic enzyme
inhibitors such as CAY10593 (phospholipase D blocker)
(Pupovac et al., 2013), antipsychotics (Hempel et al., 2013) as
well as various cations, such as Ca2+ and Mg2+ (Jiang, 2009).
While the first-generation compounds such as oATP and BBG
are still being used in some experimental paradigms, second-
generation P2RX7 antagonists offer significantly increased
specificity, albeit at significantly increased cost. This second
generation antagonists began to emerge in 2006 with the
development by Abbott Labs of disubstituted tetrazoles such
as A438079 (Nelson et al., 2006) and cyanoguanidines such
as A740003 (Honore et al., 2006). Interestingly, both classes
were previously thought to act reversibly and competitively
(Donnelly-Roberts and Jarvis, 2007). However, recent structural
data contradicted this assumption by placing A74003 not in
the ATP-binding pocket but acting via the newly identified
allosteric, non-competitive site instead (Karasawa and Kawate,
2016). Intriguingly, A438079 binding analysis is not yet available
while this compound appears to preferentially block the LP
(Haanes et al., 2012). It would be therefore interesting to
interrogate the newly available crystal structure to determine
whether A438079 and A740003 share the same binding site as
this information may help our understanding of the channel
vs. pore functionality. Another important step has been the
development of a stable, selective orally bioavailable, blood
brain barrier permeable P2RX7 antagonists suitable for the
treatment of a host of human pathologies. High-throughput
screening has led to the identfication of Glaxo GSK314181A
(Broom et al., 2008) and AstraZeneca AZ11645373 (Stokes
et al., 2006, also see Mehta et al., 2014 and Syed and Kennedy,
2012 for extensive reviews (Syed and Kennedy, 2012; Mehta
et al., 2014) followed by AZD9056, also from AstraZeneca
(Keystone et al., 2012) and CE-224,535 from Pfizer (Stock
et al., 2012). Since the development of these new drugs,
pharmacological inhibition of P2RX7 has proven to be effective
and well-tolerated treatment in multiple rodent models of
inflammatory diseases including neurological, musculoskeletal
as well as retinal, kidney, bladder, liver, lung, and skin-
based inflammatory disorders (reviewed extensively in Bartlett
et al., 2014, in models of stroke, brain trauma, hemorrhage
and also in BBB integrity loss Zhao et al., 2016) as well
as muscular dystrophy, cardiomyopathy, respiratory disorders,
inflammatory bowel disease and cancer. Additionally to the
inflammatory diseases or those with an obvious inflammatory
component, P2RX7 drugs showed efficacy in Azlheimer’s and
psychiatric disorders such as mania, depression and also prion
disease (reviewed in Bartlett et al., 2014; Savio et al., 2018).
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Unfortunately, the precise localization of P2RX7 expression in
the brain remains controversial due to non-specific antibody
binding (Anderson and Nedergaard, 2006) with p2rx7 KOmouse
brains showing strong immunoreactivity (Sim et al., 2004). A
recent progress in this area has been the development and initial
characterization of a humanized P2RX7 mouse model, where
hP2RX7 expression was localized to glutamatergic pyramidal
neurons of the hippocampus, as well as to non-neuronal
lineages including astrocytes, microglia, and oligodendrocytes
(Metzger et al., 2017). Interestingly, in yet another model, the
P2RX7_EGFP mice the receptor expression has been localized
to the dentate gyrus granule cell layer (Jimenez-Pacheco et al.,
2016). The existence of neuronal P2RX7 responses remains the
topic of debate, with arguments for both the neuronal P2RX7
responses being an important pharmacological target (Miras-
Portugal et al., 2017) but also suggesting that these responses
are due to P2RX7 expression on astrocytes or microglia instead
(Illes et al., 2017). Clearly, full understanding of the P2RX7
localisation in the brain remains elusive and would be required
for the development of targeted therapeutic approaches for the
variety of CNS diseases in which this receptor appears to play a
role.
Despite these limitations, >70 patents for P2RX7 antagonists
have been filed in the last few years, including for the use of
A438079 in depression, anxiety and bipolar disorders, triazole-
based drugs for CNS disorders and P2RX7 antagonists in
epithelial cancers (from GSK, Abbott and Cleveland University
Hospitals, respectively (Park and Kim, 2016). Moreover, trials
have been conducted in relation to several inflammatory
pathologies such as rheumatoid arthritis (Maini et al., 2006;
Keystone et al., 2012), Crohn’s (Eser et al., 2015), and basal cell
carcinoma (Gilbert et al., 2017) to name but a few. Although
AstraZeneca’s AZD9056 trials were halted due to disappointing
results, it’s more recent application to Crohn’s has been more
promising. This suggests that P2RX7 inhibition may not be
equally effective in various diseases with an inflammatory
component and potentially that some drugs may show different
efficacy in specific conditions. In this context, one remaining
questions is whether selective targeting of the channel or the
LP receptor functions would have more significant therapeutic
effect. Another consideration is the impact of the P2RX7
polymorphisms, which are numerous and which have been
demonstrated to impact various human disorders (Fuller et al.,
2009). The benefit of the recent publication of the P2RX7
3-D crystal structure is that it will be possible to utilize it in
the in silico high-throughput screening of chemical libraries
and rational drug design. Structural prediction-based screening
recently identified 3 novel competitive orthosteric antagonists.
Intriguingly, one of these compounds was reported to specifically
antagonize P2RX7 LP pore formation with no effect on the
channel function (Caseley et al., 2016). Given that this drug
binding to the eATP pocket affects LP only, it might provide
some support for the hypothesis that the channel and pore are
produced by the P2RX7 itself. However, while the publication
focused on the therapeutic potential of this new “pore blocker”
it did not consider this potentially distinguishing molecular
mechanism.
Another example of the impact of the receptor crystal
structure is the identification of the mechanism of action of
AZT and other Nucleoside Reverse Transcriptase Inhibitors
(NRTIs) at the P2RX7. These drugs have been shown previously
to be able to block this receptor functions in vitro and
to have therapeutic impact in vivo, in a number of mouse
models of human diseases (Fowler et al., 2014). Molecular
modeling showed that AZT and its derivatives occupy the
same allosteric site as the canonical antagonists and also led
to further work that proved AZT to be therapeutic in the
mouse model of Duchenne muscular dystrophy (Al-Khalidi
et al., 2018). AZT is a mainstay in the prevention of mother-
to-child HIV transmission (Van Zyl et al., 2008). Consequently,
there is extensive safety and pharmacokinetic data available
following decades of AZT use in humans, also in children
and neonates. Therefore, it is a good candidate for rapid re-
purposing for treatment of human diseases requiring P2RX7
inhibition.
An exciting development in the P2RX7 targeting is a new class
of antagonist—Multi-Target-Directed-Ligands (MTDLs), which
permit the specific delivery of P2RX7 antagonists in a previously
unattainably targeted manner. Specifically, dual NMDA-P2RX7
compounds were recently synthesized for targeting both the
excitotoxicity-induced cell death as well as the P2RX7-dependent
neuroinflammatory-induced cell death seen in Alzheimer’s
disease (Karoutzou et al., 2018). Such compounds represent an
exciting and theoretically limitless combinatorial approach to
P2RX7 inhibition.
With rational design-based drug screening set to replace
classical approaches, the number of P2RX7 antagonists should
increase further. Yet, for the rational clinical application of the
existing as well as the new drugs, we still require a significant
improvement of our basic understanding of underlying receptor
physiology and pharmacology and of its involvement in various
pathologies. Perhaps the holy grail of P2RX7 research remains the
determination of the molecular mechanism of the channel vs. the
LP opening (Karasawa et al., 2017) and also of the physiological
and pathological importance of this phenomenon.
Cancer is the paragon of P2RX7’s dual nature. P2RX7 is
ubiquitously overexpressed in cancer (Figure 3). Yet, tumor
cells appear to take advantage of the receptor responses,
without succumbing to the LP-mediated cell death cascade
activation, which would be fully expected given such significant
overexpression in the presence of abundant eATP in the tumor
environment (Young et al., 2017). Quite the reverse, tumor cells
use this P2RX7 overexpression to their significant advantage
though increases in growth, migration, the Warburg effect,
VEGF production triggering tumor neo-angiogenesis and MMP
release helping its invasion and metastasis (Young et al., 2017;
reviewed by Di Virgilio, 2016). While many tumors expressed
the “non-functional” P2RX7, there is evidence that the functional
receptor can be expressed too. Only few loss-of function
mutations have been identified in P2X7 expressed in various
tumor types (Figure 3). Thus, the systemic administration of
pharmacological P2RX7 blockers should have a potent anti-
tumor effect by preventing the high jacking of this receptor
by cancer cells. Interestingly, while this approach showed
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FIGURE 3 | P2RX7 expression is elevated in human cancers. cBioPortal (cbioportal.org) derived expression levels for P2RX7 multiple human cancer patient biopsies
from TCGA data (cancergenome.nih.gov). Noticeable, across almost all tumor types, is the significant overexpression of P2RX7 and a paucity of detected mutations.
This indicates that malignant cells express high levels of fully-functional receptors, which is an important consideration for drug treatment.
promise in some tumors, the effect was far from universal. The
problem is that P2RX7 is a significant player in the immune
response that, in turn, can inhibit growth of some tumors
(reviewed by Di Virgilio, 2016). Indeed, there are indications that
immune suppression following P2RX7 inhibition is a real and
potentially significant drawback, as tumors in p2rx7 KO mice
show accelerated growth, increased tumor size and metastasis,
recruitment and invasion, all of which reflects reduced immune
cell activation (Adinolfi et al., 2015). Perhaps the appropriate
metaphor for P2RX7 in cancer would be that of the sword
and the shield, where the sword may be blunted through
receptor blockade but at the expense of lowering the shield hand.
Hence, a successful cancer treatment with P2RX7 antagonists
should, ideally, selectively target cancer cells whilst leaving the
host immune response unscathed. In addition, a treatment
exploiting the overexpression of P2RX7 on tumor cells and
turning it against the tumor is an appealing proposition. The
aforementioned targeting of the “non-functional” P2RX7 with
specific antibodies is one example currently in clinical trials.
Another could be the development of positive modulators
of P2RX7 LP formation or compounds which effectively
upregulate or reinstate P2RX7 LP formation in tumor cells,
which overexpress either functional or “non-functional” receptor
variants. Such an approach abrogates any concerns over immune
response dampening and potentially could even boost the
anti-tumor responses as certain types of cell death trigger or
potentiate immune responses.
In conclusion, recent progress in obtaining the receptor crystal
structure, understanding the mechanism of action of structurally
unrelated antagonists and in unraveling the feedback mechanism
regulating its functions should result in a breakthrough in
targeting P2RX7 in a host of human diseases.
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